Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing
Basic Study Information
This is an international, multi-center, double-blind, placebo-controlled evaluation
valganciclovir treatment for up to 54 children (up to 4 years of age) with
virologically-confirmed congenital CMV infection and hearing loss. Subject participation
be over a six-month period and study subjects will be stratified according to age.
primary objective is to assess whether a six-week course of oral valganciclovir can
the hearing of children with congenital CMV infection who present with hearing loss.
Study Contact InformationStudy Coordinator: David W Kimberlin
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search